GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine–induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, GLP-1RAs have demonstrated considerable therapeutic promise in animal models of both PD and AD.427–429”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to its effects on metabolic regulation, GLP-1, when synthesized within the brain, exhibits neuroprotective properties.397,427,431”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 10×
“These and other actions are mediated through the G protein-coupled GLP-1R, and Ex-4 has demonstrated therapeutic value in T2DM (7).”
BackgroundMethodInfluentialDiabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“GLP-1R mRNA occurs widely throughout the brains of rodents (9) and humans (6,7,10), and both GLP-1 and Ex-4 can readily enter the brain (11) to modify feeding and satiety (12).”
BackgroundJavitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263 · cited 2×
“Administration of MPTP in mice induces a consistent dopaminergic cell loss that parallels many aspects of PD (16,20).”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 3×
“Although T2DM now occurs more often in the young, the incidence rises dramatically with age, along with that of many of other conditions, including acute and chronic neurologic disorders, exemplified by stroke (2), Parkinson’s disease (PD) and Alzheimer’s disease (AD) (3,4), which, like T2DM, were once considered rela…”
BackgroundD'Mello, S. R., Galli, C., Ciotti, T., & Calissano, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10989 · Cited by 892 · cited 1×
“cAMPmediated pathways are central to the antiapoptotic actions of GLP-1 in -cells (6–8), and the neuroprotective effects of cAMPelevating agents are seen in many neuronal cells, including sensory (24), dopaminergic (25), septal cholinergic (26), cerebellar granule (27,28), and spinal cord motor neurons (29).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“These neurotrophic/protective actions are in accordance with previous findings establishing that GLP-1R stimulation protects hippocampal neurons from amyloid- peptide–, Fe2 -, and glutamate-induced toxicity (15,32,33).”
BackgroundResultInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Mattson, M. P. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00275.x · Cited by 751 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
BackgroundSelf-citationCell death in the nervous system
Bredesen, D. E., Rao, R. V., & Mehlen, P. (2006) · Nature · doi:10.1038/nature05293 · Cited by 636 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
BackgroundGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citationGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 2×
“GLP-1R mRNA occurs widely throughout the brains of rodents (9) and humans (6,7,10), and both GLP-1 and Ex-4 can readily enter the brain (11) to modify feeding and satiety (12).”
BackgroundType 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Matsuura, K., Kabuto, H., Makino, H., & Ogawa, N. (1997) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(96)02211-x · Cited by 422 · cited 1×
“Motor function was evaluated by multiple paradigms, including mean score of behaviors, rotarod, pole test, beam walk, and open-field activity as described previously (44,45) (SI Materials and Methods).”
MethodTatton, N. A. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7489 · Cited by 411
Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380
Self-citationPerry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347
Self-citationBertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345 · cited 3×
“Our findings indicate that the neuroprotective actions of GLP-1R agonists appear to effectively translate across a number of classic cellular and animal models, including stroke and PD, as well as cholinergic ablation (14), kainic acid–induced CA3 hippocampal loss (38), and peripheral neuropathy (35).”
BackgroundRydel, R. E., & Greene, L. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1257 · Cited by 315 · cited 1×
“cAMPmediated pathways are central to the antiapoptotic actions of GLP-1 in -cells (6–8), and the neuroprotective effects of cAMPelevating agents are seen in many neuronal cells, including sensory (24), dopaminergic (25), septal cholinergic (26), cerebellar granule (27,28), and spinal cord motor neurons (29).”
BackgroundVillalba, M., Bockaert, J., & Journot, L. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-01-00083.1997 · Cited by 306 · cited 1×
“cAMPmediated pathways are central to the antiapoptotic actions of GLP-1 in -cells (6–8), and the neuroprotective effects of cAMPelevating agents are seen in many neuronal cells, including sensory (24), dopaminergic (25), septal cholinergic (26), cerebellar granule (27,28), and spinal cord motor neurons (29).”
BackgroundPerry, T., Lahiri, D. K., Chen, D., Zhou, J., Shaw, K. T. Y., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.958 · Cited by 300 · cited 8×
“Previous work has demonstrated a clear involvement of PKA; neuroprotection by GLP-1 was abolished by Rp-cAMP, which blocks cAMP activation of PKA (13).”
BackgroundInfluentialSelf-citationYamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., Drucker, D. J., & Elmquist, J. K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02939.2003 · Cited by 294 · cited 1×
“TH also is expressed in catecholamine neurons in the area postrema, and Ex-4 has been shown to significantly elevate TH levels in these neurons by inducing TH gene expression through the TH promoter (30), which contains a cAMP-responsive element (31), representing a further modulatory mechanism that may account in par…”
BackgroundHarkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A. E., Biggs, C. S., & Whitton, P. S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-19 · Cited by 289 · cited 2×
“Ex-4’s ability to improve dopaminergic markers and function when administered a week or more after 6-OHDA– or cytokine-induced apoptosis, rather than at the time of insult as in our study, is indicative of neuroregenerative action (38,39).”
The Relationship Between Diabetes Mellitus and Parkinson'S Disease
Sandyk, R. (1993) · International Journal of Neuroscience · doi:10.3109/00207459309003322 · Cited by 243 · cited 2×
“g, L-DOPA) have been reported to induce hyperglycemia (40).”
BackgroundHollander, M. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.3.317 · Cited by 236 · cited 2×
“Although T2DM now occurs more often in the young, the incidence rises dramatically with age, along with that of many of other conditions, including acute and chronic neurologic disorders, exemplified by stroke (2), Parkinson’s disease (PD) and Alzheimer’s disease (AD) (3,4), which, like T2DM, were once considered rela…”
BackgroundCyclic AMP Elevation Is Sufficient to Promote the Survival of Spinal Motor Neurons In Vitro
Hanson, M. G., Shen, S., Wiemelt, A. P., McMorris, F. A., & Barres, B. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-18-07361.1998 · Cited by 216 · cited 1×
“cAMPmediated pathways are central to the antiapoptotic actions of GLP-1 in -cells (6–8), and the neuroprotective effects of cAMPelevating agents are seen in many neuronal cells, including sensory (24), dopaminergic (25), septal cholinergic (26), cerebellar granule (27,28), and spinal cord motor neurons (29).”
BackgroundMontrose-Rafizadeh, C. (1999) · Endocrinology · doi:10.1210/en.140.3.1132 · Cited by 216
p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism
Duan, W., Zhu, X., Ladenheim, B., Yu, Q., Guo, Z., Oyler, J., Cutler, R. G., Cadet, J. L., Greig, N. H., & Mattson, M. P. (2002) · Annals of Neurology · doi:10.1002/ana.10350 · Cited by 204
Self-citationPerry, T., Holloway, H. W., Weerasuriya, A., Mouton, P. R., Duffy, K., Mattison, J. A., & Greig, N. H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.028 · Cited by 182 · cited 2×
“Our findings indicate that the neuroprotective actions of GLP-1R agonists appear to effectively translate across a number of classic cellular and animal models, including stroke and PD, as well as cholinergic ablation (14), kainic acid–induced CA3 hippocampal loss (38), and peripheral neuropathy (35).”
BackgroundSelf-citationFernagut, P. O., Diguet, E., Stefanova, N., Biran, M., Wenning, G. K., Canioni, P., Bioulac, B., & Tison, F. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00205-1 · Cited by 159 · cited 1×
“Motor function was evaluated by multiple paradigms, including mean score of behaviors, rotarod, pole test, beam walk, and open-field activity as described previously (44,45) (SI Materials and Methods).”
MethodApoptosis and protein expression after focal cerebral ischemia in rat
Li, Y., Chopp, M., Powers, C., & Jiang, N. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00524-6 · Cited by 159 · cited 1×
“p53 mRNA and protein are up-regulated shortly after stroke, leading to p53-dependent programmed cell death in penumbra (36).”
BackgroundSelf-citationApoptosis in the pathophysiology of diabetes mellitus
Lee, S. C., & Pervaiz, S. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.09.007 · Cited by 159 · cited 14×
“Although associated with different cell types in divergent areas (e.g., cortical and striatal neurons in stroke, substantia nigral and midbrain dopaminergic neurons in PD, pancreatic -cells in T2DM), parallel biochemical cascades are triggered by specific environmental and genetic signals and lead to the cellular dysf…”
BackgroundInfluentialBrain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration
Banks, W. A., During, M. J., & Niehoff, M. L. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063222 · Cited by 155 · cited 2×
“GLP-1R mRNA occurs widely throughout the brains of rodents (9) and humans (6,7,10), and both GLP-1 and Ex-4 can readily enter the brain (11) to modify feeding and satiety (12).”
BackgroundThe role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin ?
Leker, R. R. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.030 · Cited by 145
Molecular Mechanisms for Heterologous Sensitization of Adenylate Cyclase
Watts, V. J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.1.1 · Cited by 135
Perry, T., & Greig, N. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367892 · Cited by 127 · cited 1×
“These neurotrophic/protective actions are in accordance with previous findings establishing that GLP-1R stimulation protects hippocampal neurons from amyloid- peptide–, Fe2 -, and glutamate-induced toxicity (15,32,33).”
ResultSelf-citationThe glucagon-like peptides: a double-edged therapeutic sword?
Perry, T., & Greig, N. H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00160-3 · Cited by 122
Self-citationApoptotic and behavioral sequelae of mild brain trauma in mice
Tweedie, D., Milman, A., Holloway, H., Li, Y.-Z., Harvey, B., Shen, H., Pistell, P., Lahiri, D., Hoffer, B., Wang, Y., et al. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21160 · Cited by 96 · cited 1×
“Biochemical markers of cell death (caspase-3, Bax, and Bcl-2) were assessed by Western blot analysis as described previously (20,41,42).”
MethodSelf-citationLazaroff, M. A., Patankar, S., Yoon, S. O., & Chikaraishi, D. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.21579 · Cited by 95 · cited 1×
“TH also is expressed in catecholamine neurons in the area postrema, and Ex-4 has been shown to significantly elevate TH levels in these neurons by inducing TH gene expression through the TH promoter (30), which contains a cAMP-responsive element (31), representing a further modulatory mechanism that may account in par…”
BackgroundCalara, F., Taylor, K., Han, J., Zabala, E., Carr, E. M., Wintle, M. E., & Fineman, M. S. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.02.008 · Cited by 94 · cited 1×
“c) achieved plasma levels of 200 pg/mL (48 nM) in humans (34), which compare favorably to the doses studied here.”
BackgroundJeerakathil, T., Johnson, J. A., Simpson, S. H., & Majumdar, S. R. (2007) · Stroke · doi:10.1161/strokeaha.106.481390 · Cited by 76 · cited 14×
“Although associated with different cell types in divergent areas (e.g., cortical and striatal neurons in stroke, substantia nigral and midbrain dopaminergic neurons in PD, pancreatic -cells in T2DM), parallel biochemical cascades are triggered by specific environmental and genetic signals and lead to the cellular dysf…”
BackgroundInfluentialEffects of cerebral ischemia in mice deficient in Persephin
Tomac, A. C., Agulnick, A. D., Haughey, N. J., Chang, C.-F., Zhang, Y., Bäckman, C. M., Morales, M., Mattson, M. P., Wang, Y., Westphal, H., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152535899 · Cited by 72 · cited 12×
“At 15 min after left lateral ventricle administration of Ex-4 (1 M 20 L; 83 ng) or vehicle (PBS), adult male Sprague-Dawley rats were subjected to transient (60 min) right-sided MCAo (43).”
MethodInfluentialSelf-citationKew, J. N. C., Smith, D. W., & Sofroniew, M. V. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00365-7 · Cited by 62
Satoh, F., Beak, S. A., Small, C. J., Falzon, M., Ghatei, M. A., Bloom, S. R., & Smith, D. M. (2000) · Endocrinology · doi:10.1210/endo.141.4.7420 · Cited by 56
Mena, M. A., Casarejos, M. J., Bonnin, A., Ramos, J. A., & de Yébenes, J. G. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65062612.x · Cited by 55 · cited 1×
“cAMPmediated pathways are central to the antiapoptotic actions of GLP-1 in -cells (6–8), and the neuroprotective effects of cAMPelevating agents are seen in many neuronal cells, including sensory (24), dopaminergic (25), septal cholinergic (26), cerebellar granule (27,28), and spinal cord motor neurons (29).”
Background
Research works printed but not linked: 2
- R Sicree, J Shaw, P Zimmet Diabetes Atlas, ed D Gan (International Diabetes Federation, 3rd Ed, Brussels), pp. 15–103 (2006).
- 10.1210/endo.140.3.6550 · doi:10.1210/endo.140.3.6550 · Paper page
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Consistent with this, exendin-4 increases survival and levels of tyrosine hydroxylase, the key enzyme for dopamine production, in primary neuronal cultures treated with the dopaminergic toxin 6-hydroxydopamine (6-OHDA) [843].”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“Ex-4 (21 ng, i.c.v.) given 15min prior to middle cerebral artery occlusion (MCAO) reduced infarct size in wild-type but not in Glp1r / mice (Li et al., 2009).”
BackgroundMethodInfluentialHallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242
Self-citationBlock of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
“GLP-1R agonists are protective in models of stroke, traumatic brain injury (TBI), AD, and the MPTP intoxication model of PD 4,5,8,12,13 .”
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Metadata
- Authors
- Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., Brossi, A., Lahiri, D. K., Mattson, M. P., Hoffer, B. J., Wang, Y., & Greig, N. H.
- Affiliations
- National Institute on Aging (US)
- Medical University of South Carolina (US)
- National Institute on Drug Abuse (US)
- University of North Carolina at Chapel Hill (US)
- Indiana University School of Medicine (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-01-27
- Volume
- 106
- Issue
- 4
- Pages
- 1285-1290
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2633544
- OpenAlex
- W2080785707
- Cited by
- 589
- References
- 45
- Citations by year
- 2026: 18 · 2025: 39 · 2024: 39 · 2023: 24 · 2022: 33 · 2021: 49 · 2020: 41 · 2019: 40 · 2018: 43 · 2017: 34 · 2016: 41 · 2015: 45 · 2014: 34 · 2013: 33 · 2012: 27
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- University of Toronto
- National Institutes of Health
- National Institute on Aging
- National Institute on Drug Abuse
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- GLP-1 receptor, exendin-4, stroke, Parkinson's disease, dopaminergic neurons, cortical neurons, neuroprotection, MPTP mouse model, middle cerebral artery occlusion, 6-hydroxydopamine, hypoxia, oxidative stress, dopamine levels, motor function
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Cells, Cultured, Cerebral Cortex, Disease Models, Animal, Dopamine, Embryo, Mammalian, Gene Expression Regulation, Humans, Mesencephalon, Neurons, Parkinson Disease, Peptides, Venoms, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Cell Hypoxia, Treatment Outcome, Cell Death, Receptors, Glucagon, Cytoprotection, Brain Infarction, Stroke, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.